A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

Recruiting now

Conditions studied: Cancer, Immunotherapy, PD-1, PD-L1, Immune Checkpoint Therapy

In brief

The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs) across multiple oncological indications by comparing the results to actual treatment responses for cancer patients.

Key facts

Study ID: NCT06635954
Run by: Oxford Biodynamics Inc.
People needed: 2000
Starts: 2024-05-14
Expected to finish: 2027-05-14
Last updated by the study team: 2025-03-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

18 years of age or older
Stage III or IV cancer
Selected by their healthcare provider to receive the Episwitch CiRT® test according to the current evidence-based schedule (per protocol) as part of their standard of practice.
ECOG performance status ≤ 2
Clinically eligible for ICI therapy
Able to read, understand and provide written informed consent.
Willing and able to comply with the study requirements

You may not qualify if…

Pregnant or breastfeeding
History of bone marrow or organ transplant
Contra indication for receiving Immune Check Point inhibitor.

Where it is running

Eastern Connecticut Hematology and Oncology — Norwich, Connecticut, United States (enrolling)
Cancer Center of Middle Georgia — Dublin, Georgia, United States (enrolling)
Carolina Blood and Cancer Care Associates — Rock Hill, South Carolina, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.